This research service provides an introduction to systemic lupus erythematosus (SLE), disease classification and diagnosis. Research in this report overviews the current status of SLE pipeline candidates with a focus on current Phase 3 candidates, detailed timelines with accrual rate and approval estimates for U.S. and European markets, ranking of the approval likeliness for current Phase 3 candidates, rationale for pivotal program design, Phase 2 data review, and KOL commentary. A pipeline assessment is provided for all active SLE candidates in development.
Executive Summary
Methodology and Scope
Introduction
Competitive Landscape
Timeline Transparency
SLE Drug Trial Results
Product Dashboards
The Future of Treatment Decisions
Appendix
The Frost & Sullivan Story
Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.
Speak directly with our analytics experts for tailored recommendations.
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
This issue of Vital Signs discusses the change in 2015 Mammogram Guidelines, NeoGenomics' acquistion of Clarient from GE, and Tute Genomics' acquisition of Knome.
| Deliverable Type | Market Research |
|---|---|
| No Index | Yes |
| Podcast | No |
| WIP Number | 9837-00-55-00-00 |
| Is Prebook | No |
Overview of the Global Systemic Lupus Erythematosus Pipeline and the Next Three Potential Product Launches
Overview of the Global Systemic Lupus Erythematosus Pipeline and the Next Three Potential Product Launches
RELEASE DATE
22-Feb-2013
22-Feb-2013
REGION
Global
Global
Deliverable Type
Market Research
Market Research
Research Code: 9837-00-55-00-00
SKU: LS00066-GL-MR_16907
$1,500.00
In stock
SKU
LS00066-GL-MR_16907
